Bolt Biotherapeutics (BOLT) Stock Forecast, Price & News

Bolt Biotherapeutics (NASDAQ:BOLT) Frequently Asked Questions

Is Bolt Biotherapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bolt Biotherapeutics stock.
View analyst ratings for Bolt Biotherapeutics or view top-rated stocks.

Are investors shorting Bolt Biotherapeutics?

Bolt Biotherapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,620,000 shares, an increase of 40.9% from the April 15th total of 1,150,000 shares. Based on an average daily volume of 236,300 shares, the short-interest ratio is currently 6.9 days. Approximately 7.7% of the company's stock are sold short.
View Bolt Biotherapeutics' Short Interest.

When is Bolt Biotherapeutics' next earnings date?

Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Bolt Biotherapeutics.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its earnings results on Wednesday, March, 30th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.08.
View Bolt Biotherapeutics' earnings history.

What price target have analysts set for BOLT?

4 analysts have issued 1 year price targets for Bolt Biotherapeutics' stock. Their forecasts range from $5.00 to $45.00. On average, they expect Bolt Biotherapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 1,372.4% from the stock's current price.
View analysts' price targets for Bolt Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Bolt Biotherapeutics' key executives?

Bolt Biotherapeutics' management team includes the following people:

• Dr. Randall C. Schatzman, CEO & Director (Age 67, Pay $830.67k)
• Dr. Edgar G. Engleman M.D., Founder & Independent Director (Age 76, Pay $31.58k)
• Mr. William P. Quinn, Chief Financial Officer (Age 51, Pay $563.68k) (LinkedIn Profile)
• Mr. Grant Yonehiro C.F.A., M.B.A., Chief Bus. Officer (Age 58, Pay $519.98k)
• Dr. Edith A. Perez M.D., Chief Medical Officer (Age 65, Pay $627.32k)
• Dr. David Dornan Ph.D., Advisor (Age 44, Pay $580.08k)
• Ms. Karen L. Bergman, VP of Communications & Investor Relations
• Mr. Wesley Burwell, VP & Head of HR

Who are some of Bolt Biotherapeutics' key competitors?

Some companies that are related to Bolt Biotherapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO) and Exelixis (EXEL).
View all of BOLT's competitors.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP).

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.30%), Eventide Asset Management LLC (2.29%), Vanguard Group Inc. (2.26%), Renaissance Technologies LLC (0.77%), Northern Trust Corp (0.50%) and Echo Street Capital Management LLC (0.33%). Company insiders that own Bolt Biotherapeutics stock include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends for Bolt Biotherapeutics.

Which institutional investors are selling Bolt Biotherapeutics stock?

BOLT stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., BlackRock Inc., Qube Research & Technologies Ltd, and Northern Trust Corp.
View insider buying and selling activity for Bolt Biotherapeutics or view top insider-selling stocks.

Which institutional investors are buying Bolt Biotherapeutics stock?

BOLT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Echo Street Capital Management LLC, GSA Capital Partners LLP, PDT Partners LLC, and Bank of New York Mellon Corp. Company insiders that have bought Bolt Biotherapeutics stock in the last two years include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP, and William P Quinn.
View insider buying and selling activity for Bolt Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $1.63.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics has a market capitalization of $61.08 million and generates $1.26 million in revenue each year. The company earns $-98.59 million in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 91 workers across the globe.

What is Bolt Biotherapeutics' official website?

The official website for Bolt Biotherapeutics is www.boltbio.com.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-665-9295 or via email at [email protected].